Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
SC 13G

A statement of beneficial ownership of common stock by certain persons

 View HTML
0001193125-16-457617.pdf
0001193125-16-457617.rtf
0001193125-16-457617.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-16-003101.pdf
0001558370-16-003101.rtf
0001558370-16-003101.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-16-018639.pdf
0001179110-16-018639.rtf
0001179110-16-018639.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-16-018642.pdf
0001179110-16-018642.rtf
0001179110-16-018642.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-16-018641.pdf
0001179110-16-018641.rtf
0001179110-16-018641.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-16-018643.pdf
0001179110-16-018643.rtf
0001179110-16-018643.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-16-018640.pdf
0001179110-16-018640.rtf
0001179110-16-018640.xls
3

Initial filing by director officer or owner of more than ten percent.

 View HTML
0001179110-16-018638.pdf
0001179110-16-018638.rtf
0001179110-16-018638.xls
CT ORDER

CT ORDER

 View HTML
9999999997-16-016557.pdf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-16-018338.pdf
0001179110-16-018338.rtf
0001179110-16-018338.xls